Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 261

1.

Spheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype.

Saar M, Zhao H, Nolley R, Young SR, Coleman I, Nelson PS, Vessella RL, Peehl DM.

Cancer Lett. 2014 Jul 3. pii: S0304-3835(14)00330-9. doi: 10.1016/j.canlet.2014.06.014. [Epub ahead of print]

PMID:
24998678
[PubMed - as supplied by publisher]
2.

The role of the microenvironment-dormant prostate disseminated tumor cells in the bone marrow.

Lam HM, Vessella RL, Morrissey C.

Drug Discov Today Technol. 2014 Mar;11:41-7. doi: 10.1016/j.ddtec.2014.02.002.

PMID:
24847652
[PubMed - in process]
3.

Androgen receptor splice variants determine taxane sensitivity in prostate cancer.

Thadani-Mulero M, Portella L, Sun S, Sung M, Matov A, Vessella RL, Corey E, Nanus DM, Plymate SR, Giannakakou P.

Cancer Res. 2014 Apr 15;74(8):2270-82. doi: 10.1158/0008-5472.CAN-13-2876. Epub 2014 Feb 20.

PMID:
24556717
[PubMed - in process]
4.

Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment.

Larson SR, Chin J, Zhang X, Brown LG, Coleman IM, Lakely B, Tenniswood M, Corey E, Nelson PS, Vessella RL, Morrissey C.

Clin Exp Metastasis. 2014 Feb;31(2):247-56. doi: 10.1007/s10585-013-9625-2. Epub 2013 Nov 17.

PMID:
24242705
[PubMed - indexed for MEDLINE]
5.

Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling.

Nguyen HM, Ruppender N, Zhang X, Brown LG, Gross TS, Morrissey C, Gulati R, Vessella RL, Schimmoller F, Aftab DT, Corey E.

PLoS One. 2013 Oct 25;8(10):e78881. doi: 10.1371/journal.pone.0078881. eCollection 2013.

PMID:
24205338
[PubMed - in process]
Free PMC Article
6.

TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.

Nyquist MD, Li Y, Hwang TH, Manlove LS, Vessella RL, Silverstein KA, Voytas DF, Dehm SM.

Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17492-7. doi: 10.1073/pnas.1308587110. Epub 2013 Oct 7.

PMID:
24101480
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Tumor necrosis factor receptor associated factor-4: an adapter protein overexpressed in metastatic prostate cancer is regulated by microRNA-29a.

Ahmed F, Shiraishi T, Vessella RL, Kulkarni P.

Oncol Rep. 2013 Dec;30(6):2963-8. doi: 10.3892/or.2013.2789. Epub 2013 Oct 8.

PMID:
24100420
[PubMed - indexed for MEDLINE]
8.

Absolute quantification by droplet digital PCR versus analog real-time PCR.

Hindson CM, Chevillet JR, Briggs HA, Gallichotte EN, Ruf IK, Hindson BJ, Vessella RL, Tewari M.

Nat Methods. 2013 Oct;10(10):1003-5. doi: 10.1038/nmeth.2633. Epub 2013 Sep 1.

PMID:
23995387
[PubMed - indexed for MEDLINE]
9.

Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia.

Cheng HH, Mitchell PS, Kroh EM, Dowell AE, Chéry L, Siddiqui J, Nelson PS, Vessella RL, Knudsen BS, Chinnaiyan AM, Pienta KJ, Morrissey C, Tewari M.

PLoS One. 2013 Jul 30;8(7):e69239. doi: 10.1371/journal.pone.0069239. Print 2013.

PMID:
23935962
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Establishment and serial passage of cell cultures derived from LuCaP xenografts.

Young SR, Saar M, Santos J, Nguyen HM, Vessella RL, Peehl DM.

Prostate. 2013 Sep;73(12):1251-62. doi: 10.1002/pros.22610. Epub 2013 Jun 6.

PMID:
23740600
[PubMed - indexed for MEDLINE]
11.

Inhibition of CCL2 Signaling in Combination with Docetaxel Treatment Has Profound Inhibitory Effects on Prostate Cancer Growth in Bone.

Kirk PS, Koreckij T, Nguyen HM, Brown LG, Snyder LA, Vessella RL, Corey E.

Int J Mol Sci. 2013 May 21;14(5):10483-96. doi: 10.3390/ijms140510483.

PMID:
23698775
[PubMed]
Free PMC Article
12.

5α-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models.

Masoodi KZ, Ramos Garcia R, Pascal LE, Wang Y, Ma HM, O'Malley K, Eisermann K, Shevrin DH, Nguyen HM, Vessella RL, Nelson JB, Parikh RA, Wang Z.

Endocrinology. 2013 Jul;154(7):2296-307. doi: 10.1210/en.2012-2077. Epub 2013 May 13.

PMID:
23671262
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Dormancy in solid tumors: implications for prostate cancer.

Ruppender NS, Morrissey C, Lange PH, Vessella RL.

Cancer Metastasis Rev. 2013 Dec;32(3-4):501-9. doi: 10.1007/s10555-013-9422-z.

PMID:
23612741
[PubMed - in process]
14.

Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases.

Akfirat C, Zhang X, Ventura A, Berel D, Colangelo ME, Miranti CK, Krajewska M, Reed JC, Higano CS, True LD, Vessella RL, Morrissey C, Knudsen BS.

J Pathol. 2013 Jul;230(3):291-7. doi: 10.1002/path.4180.

PMID:
23420560
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Single cell transcriptomic analysis of prostate cancer cells.

Welty CJ, Coleman I, Coleman R, Lakely B, Xia J, Chen S, Gulati R, Larson SR, Lange PH, Montgomery B, Nelson PS, Vessella RL, Morrissey C.

BMC Mol Biol. 2013 Feb 16;14:6. doi: 10.1186/1471-2199-14-6.

PMID:
23414343
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Prostate cancer cell phenotypes based on AGR2 and CD10 expression.

Ho ME, Quek SI, True LD, Morrissey C, Corey E, Vessella RL, Dumpit R, Nelson PS, Maresh EL, Mah V, Alavi M, Kim SR, Bagryanova L, Horvath S, Chia D, Goodglick L, Liu AY.

Mod Pathol. 2013 Jun;26(6):849-59. doi: 10.1038/modpathol.2012.238. Epub 2013 Jan 25.

PMID:
23348903
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases.

Larson SR, Zhang X, Dumpit R, Coleman I, Lakely B, Roudier M, Higano CS, True LD, Lange PH, Montgomery B, Corey E, Nelson PS, Vessella RL, Morrissey C.

Prostate. 2013 Jun;73(9):932-40. doi: 10.1002/pros.22639. Epub 2013 Jan 17.

PMID:
23334979
[PubMed - indexed for MEDLINE]
18.

HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk.

Laitinen VH, Wahlfors T, Saaristo L, Rantapero T, Pelttari LM, Kilpivaara O, Laasanen SL, Kallioniemi A, Nevanlinna H, Aaltonen L, Vessella RL, Auvinen A, Visakorpi T, Tammela TL, Schleutker J.

Cancer Epidemiol Biomarkers Prev. 2013 Mar;22(3):452-60. doi: 10.1158/1055-9965.EPI-12-1000-T. Epub 2013 Jan 4.

PMID:
23292082
[PubMed - indexed for MEDLINE]
Free Article
19.

EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.

Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T, Xu H, Cato L, Thornton JE, Gregory RI, Morrissey C, Vessella RL, Montironi R, Magi-Galluzzi C, Kantoff PW, Balk SP, Liu XS, Brown M.

Science. 2012 Dec 14;338(6113):1465-9. doi: 10.1126/science.1227604.

PMID:
23239736
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

NADiA ProsVue prostate-specific antigen slope is an independent prognostic marker for identifying men at reduced risk of clinical recurrence of prostate cancer after radical prostatectomy.

Moul JW, Lilja H, Semmes OJ, Lance RS, Vessella RL, Fleisher M, Mazzola C, Sarno MJ, Stevens B, Klem RE, McDermed JE, Triebell MT, Adams TH.

Urology. 2012 Dec;80(6):1319-25. doi: 10.1016/j.urology.2012.06.080. Epub 2012 Oct 26.

PMID:
23107099
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk